

PATIENT

Harrison Weyalen

SPECIES

Canine

BREED

Boxer

SEX

Neutered Male

AGE

10.9 Years

WEIGHT

59 lbs

INTERPRETED BY

Eric Lindquist, DMV,
 DABVP (CFM), Cert.
 IVUSS

IMAGING PERFORMED BY

Ginny Dodd, DVM, D,
 ABVP (CFP)

HOSPITAL NAME

Ironton Animal
 Hospital

REFERRING VET

Dr. Creech

INVOICE

72728

DATE

12/23/25

PRESENTING CLINICAL SIGNS

Recurrent UTI's, some dysuria recently.

Abnormal PE/Chem/CBC/UA Results: PE: abd slightly pendulous, no distinct masses, lipomatous mass in SC of right inguinal region Repeat UA showed bacteria- had been on several rounds of antibiotics

ULTRASONOGRAPHIC EXAMINATION OF THE ABDOMEN

Urinary System

The **urinary bladder** revealed a minor amount of debris, unremarkable otherwise.

A prostatic mass was noted in this patient measuring 3.4 cm with a hypoechoic nodule or cyst measuring 1.0 cm x 0.60 cm. The mass entered into the proximal pre-prostatic urethra. Pericapsular inflammatory pattern noted around the prostate. The prostate was significantly vascular on power doppler assessment. The post-prostatic urethra was unremarkable.

The **kidneys** revealed largely normal size and structure, corticomedullary definition and ratio (cortex 1/3 of medulla) were essentially maintained with some age-related loss of curvilinear patterns regarding the capsule and C/M junction. The cortices presented largely uniform texture with some increased echogenicity expected for his age patient. Medullary structure differed distinctly from that of the cortex and no evidence of pelvic dilation was present. Left kidney measured 6.6 cm. Right kidney measured 7.05 cm.

Adrenal Glands

The **left adrenal gland** revealed an expansive nodule at the cranial pole, measuring 1.2 cm at the cranial pole and 0.58 cm at the caudal pole, and 2.6 cm in length.


The **right adrenal gland** was normal in size shape, measuring 1.86 cm x 0.51 cm at the caudal pole and 0.52 cm at the cranial pole.

Spleen

The **spleen** presented a smooth homogeneous parenchyma hyperechoic to liver and renal cortical parenchyma. The capsule was smooth without noticeable expansion or deviation from within the spleen or adjacent pathology. The splenic vasculature demonstrated normal volume without signs of congestion or thrombosis. No sonographic evidence of acute or chronic inflammatory, neoplastic, or infarctual changes were noted.

Liver

The **liver** images from right and left intercostal as well as subcostal views revealed subjectively normal liver size, contour, and structure. Some age-related parenchymal remodeling was noted but likely not clinically significant at this time. Vascular and biliary tracts were of normal volume and no evidence of congestion was noted. The gallbladder presented some dependent debris with essentially normal contour. The cystic and common bile ducts were normal. No overt evidence of active inflammatory, infiltrative or regenerative pathology was noted but should be paired with current or past LE elevations regarding any clinical significance to this presentation. The hepatic lymph nodes were unremarkable.



PATIENT

Harrison Weyalen

SPECIES

Canine

BREED

Boxer

SEX

Neutered Male

AGE

10.9 Years

WEIGHT

59 lbs

Gastrointestinal

Examination of the **gastrointestinal tract** revealed a stomach and intestine free of stasis, of normal wall thickness, acceptable curvilinear mural detail, and peristaltic activity. Small and large intestine demonstrated normal luminal chyme and stool consistency respectively. No obstructive or overt infiltrative disease was noted. No associated abnormal lymphatic activity was noted.

Pancreas

The base and limbs of the **pancreas** were observed to be largely isoechoic to surrounding omental fat. Pancreatic duct and capsular contour were acceptably normal and parenchyma respected normal curvilinear patterns. No overt evidence of active inflammatory or neoplastic disease was noted.

ULTRASONOGRAPHIC FINDINGS

- Prostatic mass with proximal urethral involvement.
- Left adrenal nodule – adenoma, adenocarcinoma, less likely pheochromocytoma.
-

INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS

Referral for oncological intervention recommended. Stent placement +/- chemotherapeutic intervention are likely best options in this patient. Serial blood pressures warranted, given the left adrenal nodule, to assess for related hypertension.

INTERPRETED BY

Eric Lindquist, DMV,
 DABVP (CFM), Cert.
 IVUSS

IMAGING PERFORMED BY

Ginny Dodd, DVM, D,
 ABVP (CFP)

HOSPITAL NAME

Ironton Animal
 Hospital

REFERRING VET


Dr. Creech

INVOICE

72728

DATE

12/23/25





PATIENT

Harrison Weyalen

SPECIES

Canine

BREED

Boxer

SEX

Neutered Male

AGE

10.9 Years

WEIGHT

59 lbs

INTERPRETED BY

Eric Lindquist, DMV,
 DABVP (CFM), Cert.
 IVUSS

IMAGING PERFORMED BY

Ginny Dodd, DVM, D,
 ABVP (CFP)

HOSPITAL NAME

Ironton Animal
 Hospital

REFERRING VET


Dr. Creech

INVOICE

72728

DATE

12/23/25





PATIENT

Harrison Weyalen

SPECIES

Canine

BREED

Boxer

SEX

Neutered Male

AGE

10.9 Years

WEIGHT

59 lbs

INTERPRETED BY

Eric Lindquist, DMV,
 DABVP (CFM), Cert.
 IVUSS

IMAGING PERFORMED BY

Ginny Dodd, DVM, D,
 ABVP (CFP)

HOSPITAL NAME

Ironton Animal
 Hospital

REFERRING VET


Dr. Creech

INVOICE

72728

DATE

12/23/25



The information and recommendations provided are based on the images presented by the referring veterinarian/sonographer. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.


Thank you for this referral. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance please contact me.

Eric Lindquist, DMV, DABVP(CFM), Cert. IVUSS,
 CEO, Owner, Founder -- SonoPath.com
info@SonoPath.com

Canine Prostatic Neoplasia

<http://www.sonopath.com/ProstaticCarcinoma>

Description: Prostatic neoplasia is frequently seen in dogs and can be diagnosed via ultrasonographic examination. The most commonly diagnosed prostatic neoplasms are adenocarcinoma and undifferentiated carcinoma. Transitional cell carcinoma (TCC) frequently spreads from the urinary bladder and urethra to the prostatic tissue (see the “Transitional Cell Carcinoma” chapter for more details). Metastatic squamous cell carcinoma, lymphoma, hemangiosarcoma, and leiomyosarcoma have been reported, but are less prevalent. Prostatic neoplasia has been documented in cats, but is quite rare.



PATIENT

Harrison Weyalen

SPECIES

Canine

BREED

Boxer

SEX

Neutered Male

AGE

10.9 Years

WEIGHT

59 lbs

INTERPRETED BY

Eric Lindquist, DMV,
 DABVP (CFM), Cert.
 IVUSS

IMAGING PERFORMED BY

Ginny Dodd, DVM, D,
 ABVP (CFP)

HOSPITAL NAME

Ironton Animal
 Hospital

REFERRING VET

Dr. Creech

INVOICE

72728

DATE


12/23/25

Clinical Signs: Prostatic neoplasia presents in both neutered and intact males; however, a 2002 study suggested that neutered males were at greater risk for developing prostatic neoplasia than intact males. Typically, prostatic neoplasia is seen in older dogs (mean age of 10 years). Breed predilection includes mixed breed dogs, Shetland Sheepdogs, Dobermans, Scottish Terriers, and Airedale Terriers. Clinical signs and commonly reported signs from owners typically include: stranguria, frequent urinations, hematuria, dyschezia, weight loss, and decreased appetite. Other findings upon physical examination include fever, ataxia, pain upon rectal examination, and pain upon spinal palpation.

Diagnostics: Ultrasonographic examination should be performed if prostatic neoplasia is suspected. Common ultrasonographic findings include an enlarged, irregular prostate that typically has a hypoechoic appearance. Multifocal, poorly coalescing hyperechoic foci are also seen in prostatic malignancies. Hyperechoic foci are due to mineralization of the prostate; they cause far field shadowing. Cystic components can also be observed and are thought to indicate abscessation and/or necrosis. It can be difficult to differentiate chronic bacterial prostatitis from a prostatic neoplasia; however, regional lymphadenopathy is much more common with prostatic neoplasia than it is with chronic bacterial prostatitis. Malignancies of the prostate have often metastasized by the time of diagnosis. Frequent sites of metastases include the sublumbar lymph nodes, the pelvis, lumbar vertebrae, and the lungs. If metastases to the pelvis or lumbar vertebrae have occurred, bony lysis will often be noted radiographically. Metastasis to the liver, brain, kidney and spleen may occur. A definitive diagnosis of a prostatic neoplasm can be achieved through biopsy as well as fine needle aspiration (FNA) or through ultrasound-guided traumatic catheterization.

A complete and thorough workup includes a CBC, biochemical profile, urinalysis, as well as three radiographic views of the thorax, an abdominal ultrasound, and an ultrasound-guided prostatic biopsy or FNA, if indicated. Urinalysis may reveal hematuria and pyuria. Prostatic fluid analysis can also be helpful in identifying neoplastic cells.

Treatment: Unfortunately, once diagnosed, prostatic carcinoma offers a poor prognosis; prostatectomy, chemotherapy, and radiation therapy have proven unsuccessful in improving quality or length of life. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as deracoxib, meloxicam, and piroxicam, have been used for their palliative, anti-neoplastic properties with prostatic carcinomas. Certain tumors, including various carcinomas (e.g. TCC, prostatic carcinoma, mammary carcinoma, squamous cell carcinoma) overexpress COX-2, which converts arachidonic acid to prostaglandin G2 (PGG2)/prostaglandin H2 (PGH2), and ultimately to prostaglandin E2 (PGE2). The metabolite, PGE2, is associated with increased inflammation, tumor invasiveness, angiogenesis, and reduced apoptosis. In vivo and in vitro, NSAIDs inhibit COX-2, resulting in the suppression of PGE2, and thereby inhibiting tumor growth and metastasis. This effect has been achieved with both non-selective COX inhibitors as well as COX-2 inhibitors (the latter will suppress COX-1 at increased doses).



PATIENT

Harrison Weyalen

SPECIES

Canine

BREED

Boxer

SEX

Neutered Male

AGE

10.9 Years

WEIGHT

59 lbs

INTERPRETED BY

Eric Lindquist, DMV,
 DABVP (CFM), Cert.
 IVUSS

IMAGING PERFORMED BY

Ginny Dodd, DVM, D,
 ABVP (CFP)

HOSPITAL NAME

Ironton Animal
 Hospital

REFERRING VET

Dr. Creech

INVOICE

72728

DATE

12/23/25

Some cases of prostatic carcinoma are managed palliatively with cyst/abscess ultrasound-guided drainage, antibiotic infusion, systemic antibiotics, and NSAID treatment and/or chemotherapy. Anecdotally, it has been observed that patients that often present clinical signs of hematuria or dysuria owing to cyst or abscess formation may be treated with repeat ultrasound-guided drainage. This appears to work especially well if there is a considerable cystic component to the prostatic tumor. The key is to image the prostate adequately, drain any cysts that are present, sample the abnormal parenchyma (FNA or biopsy), and potentially infuse antibiotics directly into the cystic cavities if a suppurative fluid is retrieved. The patient should be monitored clinically over time and reevaluated to see if cysts recur. Every case responds differently to treatment, and the behavior of parenchymal and cystic growth will vary.

Currently, investigational studies involving fluoroscopic-guided direct chemotherapeutic embolization through the iliac arteries as well as urethral stent placement are offered by select tertiary veterinary facilities that have an interventional radiology department. Ultrasound-guided endoscopic diode laser ablation through a perineal urethrostomy is also being attempted as a salvage and palliative procedure.

Conclusion: Prostatic neoplasia is more commonly detected in neutered male dogs than intact males. Diagnosis is typically obtained using ultrasound, cytology, and histopathology. Unfortunately, traditional therapy typically yields a guarded to poor long-term prognosis, but palliation with NSAIDs and/or chemotherapy can temporarily improve clinical signs. Investigational techniques may provide additional therapeutic options but are currently experimental.

References:

Cerf DJ, Lindquist EC. Palliative ultrasound-guided endoscopic laser ablation of transitional cell carcinomas of the lower urinary tract in dogs. *J Am Vet Med Assoc* 2012;240(1):51-60.


Culp, WTN. Interventional oncology and the management of urinary tract cancer. Proceedings from the American College of Veterinary Internal Medicine, New Orleans, LA, May 30-June 2, 2012.

Francey T. Prostatic Diseases. In: Ettinger SJ, Feldman EC, eds. *Textbook of Veterinary Internal Medicine 7th ed.* Philadelphia, PA: WB Saunders; 2010:2047-58.

Hecht S. Male Reproductive Tract. In: Pennick D, D'Anjou MA, eds. *Atlas of Small Animal Ultrasonography.* Ames, IA: Blackwell Publishing; 2008:417-43.

Milner RJ. Do NSAIDs make a difference in cancer. Proceedings from the American College of Veterinary Internal Medicine, Denver, CO, June 15-18, 2011.

Mohammed SI, Khan KN, Sellers RS, et al. Expression of cyclooxygenase-1 and 2 in naturally-occurring canine cancer. *Prostag Leukotr Ess* 2004;70(5):479-83.



PATIENT

Harrison Weyalen

SPECIES

Canine

BREED

Boxer

SEX

Neutered Male

AGE

10.9 Years

WEIGHT

59 lbs

INTERPRETED BY

Eric Lindquist, DMV,
DABVP (CFM), Cert.
IVUSS

**IMAGING
PERFORMED BY**

Ginny Dodd, DVM, D,
ABVP (CFP)

HOSPITAL NAME

Ironton Animal
Hospital

REFERRING VET

Dr. Creech

INVOICE

72728

DATE

12/23/25

Nyland, TG, Matoon JS. *Small Animal Diagnostic Ultrasound 2nd ed.* Philadelphia, PA: WB Saunders; 2002:250-66.

Sorenmo KU, Goldschmidt MH, Shofer FS, et al. Evaluation of cyclooxygenase-1 and cyclooxygenase-2 expression and the effect of cyclooxygenase inhibitors in canine prostatic carcinoma. *Vet Comp Oncol* 2004;2(1):13-23.